Royal Bank of Canada reaffirmed their sector perform rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. Royal Bank of Canada currently has a $74.00 price target on the biopharmaceutical company’s stock.
A number of other brokerages have also weighed in on GILD. UBS Group cut their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a neutral rating on the stock in a research report on Wednesday, April 17th. Barclays cut their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an equal weight rating on the stock in a research report on Monday, April 29th. Wells Fargo & Company cut their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a report on Monday, March 4th. StockNews.com upgraded shares of Gilead Sciences from a buy rating to a strong-buy rating in a report on Saturday, April 27th. Finally, Oppenheimer reiterated an outperform rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and an average price target of $83.47.
Check Out Our Latest Stock Report on GILD
Gilead Sciences Stock Performance
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $1.37 earnings per share. As a group, research analysts predict that Gilead Sciences will post 3.75 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a dividend of $0.77 per share. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.49%. Gilead Sciences’s dividend payout ratio is currently 855.56%.
Insider Activity
In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.29% of the company’s stock.
Institutional Investors Weigh In On Gilead Sciences
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after acquiring an additional 2,910,147 shares during the last quarter. Capital World Investors raised its holdings in shares of Gilead Sciences by 1.4% in the 1st quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company’s stock worth $6,189,435,000 after acquiring an additional 1,133,281 shares during the last quarter. Capital Research Global Investors raised its holdings in shares of Gilead Sciences by 2.7% in the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock worth $4,486,296,000 after acquiring an additional 1,589,240 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Gilead Sciences by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after acquiring an additional 2,350,550 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Gilead Sciences by 0.9% in the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock worth $1,267,207,000 after acquiring an additional 158,794 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
- Five stocks we like better than Gilead Sciences
- How to Capture the Benefits of Dividend Increases
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Stock Average Calculator
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is a Dividend King?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.